10 not yet recruiting, 2 recruiting, 1 enrolling by invitation. 13 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Not yet recruiting 10, Recruiting 2, Enrolling by invitation 1 |
| Phase 1 | 4 | Not yet recruiting 2, Enrolling by invitation 1, Recruiting 1 |
Follow HSCT: new trials by email Literature Review of HSCT trials Research Report on HSCT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. Sonrotoclax, cladribine, and standard-dose cytarabine - AML (Acute Myelogenous Leukemia, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-09-01 | 2026-08-11 |
| Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients Tezepelumab - Bronchiolitis Obliterans Syndrome (BOS), HSCT | Phase 2 | Recruiting | Hopital Foch | 36 | 2026-06-24 | 2026-08-18 |
| Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis Gecacitinib (also known as Jaktinib) - Myelofibrosis (MF), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 39 | 2026-03-16 | 2026-03-13 |
| Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). Gecacitinib - cGVHD, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2026-03-16 | 2026-03-17 |
| The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT Luspatercept - HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-14 | 2026-03-04 |
| Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL Olverembatinib+INO - HSCT, Ph+ ALL | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-14 | 2026-03-02 |
| Zuberitamab for EBV Infection Post-Allo-HSCT Zuberitamab - HSCT, EBV Infection | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-01-14 | 2025-12-03 |
| Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome Treosulfan (Treo) - HSCT, Nijmegen Breakage Syndrome | Phase 2 | Not yet recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 24 | 2025-12-30 | 2026-01-05 |
| Modified Conditioning Regimen for CML-BP Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie - CML,Blast Phase, HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2025-12-15 | 2025-12-02 |
| Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia - Aplastic Anaemia, HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-01-31 | 2025-01-10 |
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation. - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2024-11-01 | 2024-10-26 |
| Assessing Pulmonary Changes in HSCT Hyperpolarized 129 Xenon - HSCT, Respiratory | Phase 1 / Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 550 | 2024-07-24 | 2026-09-16 |
| Technical Development of Xe MRI Hyperpolarized 129 Xenon - HSCT, Lung Transplant Recipient | Phase 1 / Phase 2 | Enrolling by invitation | Children's Hospital Medical Center, Cincinnati | 550 | 2024-01-01 | 2026-09-16 |
Anemia, Aplastic (1) · Bronchial Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Epstein-Barr Virus Infections (1) · Leukemia, Myeloid, Acute (1) · Nijmegen Breakage Syndrome (1) · Primary Myelofibrosis (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Bone Marrow Diseases (2) · Anemia (1) · Bone Marrow Failure Disorders (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · DNA Repair-Deficiency Disorders (1) · DNA Virus Infections (1) · Graft vs Host Disease (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Infections (1) · Leukemia (1)
Cladribine (1) · Cytarabine (1) · Melphalan (1) · luspatercept (1) · tezepelumab (1) · treosulfan (1)
Institute of Hematology & Blood Diseases Hospital, China (9) · Children's Hospital Medical Center, Cincinnati (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Hopital Foch (1)
United States (2) · France (1)